Cargando…

The impact of cathelicidin, the human antimicrobial peptide LL-37 in urinary tract infections

BACKGROUND: The defense mechanisms of the urinary tract are attributed mainly to the innate immune system and the urinary tract urothelium which represent the first line of defense against invading pathogens and maintaining sterility of the urinary tract. There are only a few publications regarding...

Descripción completa

Detalles Bibliográficos
Autores principales: Babikir, Ibrahim H., Abugroun, Elsir A., Bilal, Naser Eldin, Alghasham, Abdullah Ali, Abdalla, Elmuataz Elmansi, Adam, Ishag
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759217/
https://www.ncbi.nlm.nih.gov/pubmed/29310594
http://dx.doi.org/10.1186/s12879-017-2901-z
_version_ 1783291155329318912
author Babikir, Ibrahim H.
Abugroun, Elsir A.
Bilal, Naser Eldin
Alghasham, Abdullah Ali
Abdalla, Elmuataz Elmansi
Adam, Ishag
author_facet Babikir, Ibrahim H.
Abugroun, Elsir A.
Bilal, Naser Eldin
Alghasham, Abdullah Ali
Abdalla, Elmuataz Elmansi
Adam, Ishag
author_sort Babikir, Ibrahim H.
collection PubMed
description BACKGROUND: The defense mechanisms of the urinary tract are attributed mainly to the innate immune system and the urinary tract urothelium which represent the first line of defense against invading pathogens and maintaining sterility of the urinary tract. There are only a few publications regarding cathelicidin (LL-37) and a urinary tract infection (UTI). This study was done to investigate the plasma and urine levels of human LL-37 in patients with UTI. METHODS: A case-control study was conducted at Omdurman Hospital, Sudan during the period from August 2014 to May 2017. The cases were patients with confirmed UTI and the controls were healthy volunteers without UTI. Sociodemographic and clinical data were obtained from each participant using questionnaires. Urine cultures and antimicrobial susceptibility were tested. Plasma and urine levels of LL-37 were determined using an enzyme-linked immunosorbent assay (ELISA) kit. SPSS (version 16.0) was used for analyses. RESULTS: Cases and controls (87 in each arm) were matched according to their basic characteristics. Compared with controls, the median (inter-quartile) LL-37 level in plasma [2.100 (1.700–2.700) vs. 1.800 (1.000–2.200) ng/ml, P = 0.002] and in urine [0.900 (0.300–1.600) vs. 0.000 (0.000–1.000) ng/mg creatinine, P < 0.001] was significantly higher in cases. There was no significant difference in the median plasma [2.1 (1.7–2.9) vs. 2.000 (1.700–2.400) ng/ml, P = 0.561] and urine [0.850 (0.275–2.025) vs. 0.900 (0.250–1.350) ng/mg creatinine, P = 0.124]. The uropathogenic Escherichia coli (UPEC) was the predominant isolate, n = 38 (43.7%). LL-37 levels between the E. coli isolates and the other isolated organisms. There was no significant correlation between plasma and urine LL-37 levels (r = 0.221), even when the data of the cases were analyzed separately. CONCLUSION: LL-37 is notably increased among patients with UTI compared with normal control subjects. Severity of UTI increases the levels of LL-37. The increased level was not only in the patient’s urine, but has also been observed in the patient’s plasma. Detection of increased levels of LL-37 could help to differentiate subjects with suspected UTI. Accordingly, LL-37 could act as a good marker for diagnosing UTIs.
format Online
Article
Text
id pubmed-5759217
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57592172018-01-10 The impact of cathelicidin, the human antimicrobial peptide LL-37 in urinary tract infections Babikir, Ibrahim H. Abugroun, Elsir A. Bilal, Naser Eldin Alghasham, Abdullah Ali Abdalla, Elmuataz Elmansi Adam, Ishag BMC Infect Dis Research Article BACKGROUND: The defense mechanisms of the urinary tract are attributed mainly to the innate immune system and the urinary tract urothelium which represent the first line of defense against invading pathogens and maintaining sterility of the urinary tract. There are only a few publications regarding cathelicidin (LL-37) and a urinary tract infection (UTI). This study was done to investigate the plasma and urine levels of human LL-37 in patients with UTI. METHODS: A case-control study was conducted at Omdurman Hospital, Sudan during the period from August 2014 to May 2017. The cases were patients with confirmed UTI and the controls were healthy volunteers without UTI. Sociodemographic and clinical data were obtained from each participant using questionnaires. Urine cultures and antimicrobial susceptibility were tested. Plasma and urine levels of LL-37 were determined using an enzyme-linked immunosorbent assay (ELISA) kit. SPSS (version 16.0) was used for analyses. RESULTS: Cases and controls (87 in each arm) were matched according to their basic characteristics. Compared with controls, the median (inter-quartile) LL-37 level in plasma [2.100 (1.700–2.700) vs. 1.800 (1.000–2.200) ng/ml, P = 0.002] and in urine [0.900 (0.300–1.600) vs. 0.000 (0.000–1.000) ng/mg creatinine, P < 0.001] was significantly higher in cases. There was no significant difference in the median plasma [2.1 (1.7–2.9) vs. 2.000 (1.700–2.400) ng/ml, P = 0.561] and urine [0.850 (0.275–2.025) vs. 0.900 (0.250–1.350) ng/mg creatinine, P = 0.124]. The uropathogenic Escherichia coli (UPEC) was the predominant isolate, n = 38 (43.7%). LL-37 levels between the E. coli isolates and the other isolated organisms. There was no significant correlation between plasma and urine LL-37 levels (r = 0.221), even when the data of the cases were analyzed separately. CONCLUSION: LL-37 is notably increased among patients with UTI compared with normal control subjects. Severity of UTI increases the levels of LL-37. The increased level was not only in the patient’s urine, but has also been observed in the patient’s plasma. Detection of increased levels of LL-37 could help to differentiate subjects with suspected UTI. Accordingly, LL-37 could act as a good marker for diagnosing UTIs. BioMed Central 2018-01-08 /pmc/articles/PMC5759217/ /pubmed/29310594 http://dx.doi.org/10.1186/s12879-017-2901-z Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Babikir, Ibrahim H.
Abugroun, Elsir A.
Bilal, Naser Eldin
Alghasham, Abdullah Ali
Abdalla, Elmuataz Elmansi
Adam, Ishag
The impact of cathelicidin, the human antimicrobial peptide LL-37 in urinary tract infections
title The impact of cathelicidin, the human antimicrobial peptide LL-37 in urinary tract infections
title_full The impact of cathelicidin, the human antimicrobial peptide LL-37 in urinary tract infections
title_fullStr The impact of cathelicidin, the human antimicrobial peptide LL-37 in urinary tract infections
title_full_unstemmed The impact of cathelicidin, the human antimicrobial peptide LL-37 in urinary tract infections
title_short The impact of cathelicidin, the human antimicrobial peptide LL-37 in urinary tract infections
title_sort impact of cathelicidin, the human antimicrobial peptide ll-37 in urinary tract infections
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759217/
https://www.ncbi.nlm.nih.gov/pubmed/29310594
http://dx.doi.org/10.1186/s12879-017-2901-z
work_keys_str_mv AT babikiribrahimh theimpactofcathelicidinthehumanantimicrobialpeptidell37inurinarytractinfections
AT abugrounelsira theimpactofcathelicidinthehumanantimicrobialpeptidell37inurinarytractinfections
AT bilalnasereldin theimpactofcathelicidinthehumanantimicrobialpeptidell37inurinarytractinfections
AT alghashamabdullahali theimpactofcathelicidinthehumanantimicrobialpeptidell37inurinarytractinfections
AT abdallaelmuatazelmansi theimpactofcathelicidinthehumanantimicrobialpeptidell37inurinarytractinfections
AT adamishag theimpactofcathelicidinthehumanantimicrobialpeptidell37inurinarytractinfections
AT babikiribrahimh impactofcathelicidinthehumanantimicrobialpeptidell37inurinarytractinfections
AT abugrounelsira impactofcathelicidinthehumanantimicrobialpeptidell37inurinarytractinfections
AT bilalnasereldin impactofcathelicidinthehumanantimicrobialpeptidell37inurinarytractinfections
AT alghashamabdullahali impactofcathelicidinthehumanantimicrobialpeptidell37inurinarytractinfections
AT abdallaelmuatazelmansi impactofcathelicidinthehumanantimicrobialpeptidell37inurinarytractinfections
AT adamishag impactofcathelicidinthehumanantimicrobialpeptidell37inurinarytractinfections